PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 140.8% in March

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the target of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 11,335 shares, a growth of 140.8% from the February 26th total of 4,707 shares. Based on an average trading volume of 5,784 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.0% of the company’s shares are sold short.

PureTech Health Price Performance

NASDAQ:PRTC opened at $15.74 on Thursday. PureTech Health has a 1 year low of $13.30 and a 1 year high of $20.00. The stock has a 50-day moving average price of $17.66 and a two-hundred day moving average price of $17.30.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of PureTech Health in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On PureTech Health

Several institutional investors have recently modified their holdings of PRTC. Diadema Partners LP acquired a new position in shares of PureTech Health in the 2nd quarter valued at approximately $126,000. Lansdowne Partners UK LLP acquired a new stake in PureTech Health during the 3rd quarter worth approximately $260,973,000. Finally, Pentwater Capital Management LP raised its holdings in PureTech Health by 50.0% during the 3rd quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock worth $1,388,000 after buying an additional 25,000 shares during the period. Institutional investors own 0.04% of the company’s stock.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.